Commentary

Video

Dr Murthy on the Use of CAR T-Cell Therapy in Elderly or Frail Patients With B-Cell Lymphomas

Hemant S. Murthy, MD, discusses the evolving use of CAR T-cell therapy for elderly or frail patients with relapsed/refractory B-cell lymphomas.

Hemant S. Murthy, MD, hematologist/oncologist, physician, Mayo Clinic, discusses the evolving use of CAR T-cell therapy for elderly or frail patient populations withrelapsed/refractory B-cell lymphomas.

Murthy begins by stating that current registry studies, including a large study based in Germany, have demonstrated the feasibility of administering CAR T-cell therapy to elderly patients with B-cell lymphomas. These studies did not reveal significant variation in the frequency of treatment-related cytokine release syndrome based on age in patients with B-cell lymphomas who were treated with CAR T-cell therapy. However, elderly patients tended to experience more immune effector cell–associated neurotoxicity syndrome.

To elucidate whether CAR T-cell therapy is a viable treatment alternative for patients with aggressive relapsed/refractory B-cell lymphomas who are deemed ineligible for autologous stem cell transplant (ASCT), the open-label, phase 2 ALYCANTE trial (NCT04531046) evaluated the efficacy and safety of axicabtagene ciloleucel (Yescarta; axi-cel) in the second-line setting, Murthy details. ASCT ineligibility was largely determined by age, prior treatment with ASCT, and a Hematopoietic Cell Transplantation–specific Comorbidity Index score of 3 or higher, he expands. The ALYCANTE trial employed a broad set of exclusion criteria. This included pulmonary complications, cardiac issues, pleural effusions, and hepatitis, Murthy states.

Results demonstrated that axi-cel produced a complete metabolic response (CMR) rate of 71% at 3 months vs an expected 12% CMR rate with the standard of care based on historical controls, meeting the study's primary end point (n=44; 95% CI, 58.1%–81.8%). At 6 months, 59.7% of patients (n=37) who received axi-cel continued to exhibit a CMR. Additionally, patients experienced a treatment-related mortality rate of 9.7% with axi-cel, which was higher than the 1% to 2% rate historically associated with ASCT, Murthy reports.

Although the ALYCANTE trial shows promising results with axi-cel, it also underscores the ongoing challenge of identifying and defining which patients are ineligible for CAR T-cell therapy, Murthy emphasizes. Patient selection remains a work in progress, with ongoing studies aiming to refine this process, Murthy concludes.

Related Videos
Kimmie Ng, MD, MPH
Marina Chiara Garassino, MD
Elias Jabbour, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Rahul Banerjee, MD, FACP
Seth Wander, MD, PhD
Piotr Rutkowski, MD
Javier Martín Broto MD, PhD
Nicolas Girard, MD
Thach-Giao Truong, MD, medical director, Melanoma Program, Cleveland Clinic
Guru P. Sonpavde, MD